APA (7th ed.) Citation

LG, P., SS, R., TE, C., JS, L., L, U., RB, C., . . . M, R. (2022). First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(2), 289. https://doi.org/10.1016/j.jtho.2021.09.010

Chicago Style (17th ed.) Citation

LG, Paz-Ares, et al. "First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 17, no. 2 (2022): 289. https://doi.org/10.1016/j.jtho.2021.09.010.

MLA (9th ed.) Citation

LG, Paz-Ares, et al. "First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 17, no. 2, 2022, p. 289, https://doi.org/10.1016/j.jtho.2021.09.010.